Increased rate of CD4+ T-Cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in singapore

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Ng, Oon Tek ^a,b   Lin, Li ^b   Laeyendecker, Oliver ^a,c   Quinn, Thomas C ^a,c   Sun, Yong Jiang ^b   Lee, Cheng Chuan ^b   Leo, Yee Sin ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SEROCONVERSION; SINGAPORE; SURVIVAL RATE; VIRUS LOAD; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; SINGAPORE; TIME FACTORS; YOUNG ADULT;

EID: 79551533693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015738     Document Type: Article

References (18)

1. Joint United Nations Program on HIV/AIDS (UNAIDS) WHOW (2007) AIDS Epidemic Update: November 2009. UNAIDS.
2. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM (2008) The challenge of HIV-1 subtype diversity. New England Journal of Medicine 358: 1590-1602.
3. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, et al. (2002) Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. Journal of Infectious Diseases 185: 1244-1250.
4. Keller M, Lu Y, Lalonde RG, Klein MB (2009) Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS 23: 731-737.
5. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, et al. (2010) Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 13: 4.
6. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, et al. (2007) The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 21 Suppl 6: S39-46.
7. Nelson KE, Costello C, Suriyanon V, Sennun S, Duerr A (2007) Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992-2007. AIDS 21 Suppl 6: S47-54.
8. CASCADE Collaboration (Concerted Action on SeroConversion to AIDS and Death in Europe) (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative reanalysis. Lancet 355: 1131-1137.
9. Lee CC, Sun YJ, Barkham T, Leo YS (2009) Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naive seroconverters in Singapore. HIV Med 10: 370-377.
10. USA Department of Health and Human Services Panel on antiretroviral guidelines for adults and adolescents - a working group of the Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Available: http://aidsinfo.nih.gov/contentfiles/Adu?ltandAdolescentGL.pdf. Accessed 2008 Jan 29.
11. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, et al. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58: 1-207; quiz CE201-204.
12. Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38: 963-974.
13. CASCADE Collaboration (Concerted Action on SeroConversion to AIDS and Death in Europe((2003) Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. Journal of Acquired Immune Deficiency Syndromes 34: 76-83.
14. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, et al. (2008) Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. Journal of Infectious Diseases 197: 707-713.
15. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, et al. (2007) HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. Journal of Infectious Diseases 195: 1177-1180.
16. Kiwanuka N, Robb M, Laeyendecker O, Kigozi G, Wabwire-Mangen F, et al. (2009) HIV-1 Viral Subtype Differences in the Rate of CD4+ T-Cell Decline Among HIV Seroincident Antiretroviral Naive Persons in Rakai District, Uganda. Journal of Acquired Immune Deficiency Syndromes.
17. WHO (2008) World Health Organization Statistical Information System: Core Health Indicators. World Health Organization.
18. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, et al. (2001) Viral load differences in early infection with two HIV-1 subtypes. AIDS 15: 683-691.